The Antithrombin Market is estimated at US$1.6 billion in 2026 and is projected to grow at a CAGR of 6.6% to reach US$2.7 billion by 2034.
Core applications include antithrombin deficiency management, perioperative coagulation support, obstetric risk management, critical care support, and specialty hematology treatment. Demand reflects the need for effective management of rare coagulation disorders, specialist hospital demand, awareness of thrombosis risk in vulnerable patients, and established use in defined clinical.
This product will be delivered within 1-3 business days.
Market Overview
The Antithrombin Market covers plasma derived and recombinant antithrombin products used to manage inherited deficiency, coagulation risk, and specialist perioperative or critical care anticoagulation support. Its value chain includes plasma collection networks, biopharmaceutical manufacturers, specialty distributors, hospitals, hematologists, pharmacies, and reimbursement support providers.Core applications include antithrombin deficiency management, perioperative coagulation support, obstetric risk management, critical care support, and specialty hematology treatment. Demand reflects the need for effective management of rare coagulation disorders, specialist hospital demand, awareness of thrombosis risk in vulnerable patients, and established use in defined clinical.
Market Segmentation
By Usage
- Therapeutics
- Diagnostics
- Research
- Other
By Type
- Anticoagulant
- Antiplatelet
- Thrombolytic Drugs
By Source
- Human
- Recombinant Goat Milk
- Others
By Route of Administration
- Oral
- Parenteral
Key Companies Analysed
- Takeda
- Grifols
- CSL Behring
- LFB
- Kedrion Biopharma
- Baxter
- Octapharma
- Biotest
- Pfizer
- Bayer
- Sanofi
- Boehringer Ingelheim
- Fresenius Kabi
- Kamada
- Kedrion
- Bristol Myers Squibb
- Roche
- Merck & Co
- AbbVie
- Takeda Rare Disease
Geographic Coverage
- North America - Market data and outlook to 2034
- United States
- Canada
- Mexico
- Europe - Market data and outlook to 2034
- Germany
- United Kingdom
- France
- Italy
- Spain
- Netherlands
- Switzerland
- Poland
- Sweden
- Russia
- Asia-Pacific - Market data and outlook to 2034
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Malaysia
- Vietnam
- Middle East and Africa - Market data and outlook to 2034
- Saudi Arabia
- South Africa
- Iran
- UAE
- Egypt
- South and Central America - Market data and outlook to 2034
- Brazil
- Argentina
- Chile
- Peru
Report Delivery and Support
- Updated PDF report and an MS Excel workbook containing market tables and figures.
- 7-day post-sale analyst support for clarifications and in-scope supplementary data.
- Complimentary report update covering the latest available data and relevant market developments.
This product will be delivered within 1-3 business days.
Table of Contents
1. Contents and Report Guide
2. Global Antithrombin Market Overview
3. Antithrombin Market Dynamics
4. Antithrombin Market Strategic Analysis
5. Global Antithrombin Market Size, Share and Forecast, 2025-2034
6. North America Antithrombin Market Outlook to 2034
7. Europe Antithrombin Market Outlook to 2034
8. Asia-Pacific Antithrombin Market Outlook to 2034
9. Middle East and Africa Antithrombin Market Outlook to 2034
10. South and Central America Antithrombin Market Outlook to 2034
11. Antithrombin Market Competitive Landscape
12. Appendix
Companies Mentioned
- Takeda
- Grifols
- CSL Behring
- LFB
- Kedrion Biopharma
- Baxter
- Octapharma
- Biotest
- Pfizer
- Bayer
- Sanofi
- Boehringer Ingelheim
- Fresenius Kabi
- Kamada
- Kedrion
- Bristol Myers Squibb
- Roche
- Merck & Co
- AbbVie
- Takeda Rare Disease
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | October 2026 |
| Forecast Period | 2026 - 2034 |
| Estimated Market Value ( USD | $ 1.6 Billion |
| Forecasted Market Value ( USD | $ 2.7 Billion |
| Compound Annual Growth Rate | 6.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
